Literature DB >> 14966570

Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation.

Devashish Kothapalli1, Ilia Fuki, Kamilah Ali, Sheryl A Stewart, Liang Zhao, Ron Yahil, David Kwiatkowski, Elizabeth A Hawthorne, Garret A FitzGerald, Michael C Phillips, Sissel Lund-Katz, Ellen Puré, Daniel J Rader, Richard K Assoian.   

Abstract

HDL and its associated apo, APOE, inhibit S-phase entry of murine aortic smooth muscle cells. We report here that the antimitogenic effect of APOE maps to the N-terminal receptor-binding domain, that APOE and its N-terminal domain inhibit activation of the cyclin A promoter, and that these effects involve both pocket protein-dependent and independent pathways. These antimitogenic effects closely resemble those seen in response to activation of the prostacyclin receptor IP. Indeed, we found that HDL and APOE suppress aortic smooth muscle cell cycle progression by stimulating Cox-2 expression, leading to prostacyclin synthesis and an IP-dependent inhibition of the cyclin A gene. Similar results were detected in human aortic smooth muscle cells and in vivo using mice overexpressing APOE. Our results identify the Cox-2 gene as a target of APOE signaling, link HDL and APOE to IP action, and describe a potential new basis for the cardioprotective effect of HDL and APOE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14966570      PMCID: PMC338263          DOI: 10.1172/JCI19097

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Analysis of promoter binding by the E2F and pRB families in vivo: distinct E2F proteins mediate activation and repression.

Authors:  Y Takahashi; J B Rayman; B D Dynlacht
Journal:  Genes Dev       Date:  2000-04-01       Impact factor: 11.361

Review 2.  COX-2 and beyond: Approaches to prostaglandin inhibition in human disease.

Authors:  Garret A FitzGerald
Journal:  Nat Rev Drug Discov       Date:  2003-11       Impact factor: 84.694

3.  Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth?

Authors:  L Paka; I J Goldberg; J C Obunike; S Y Choi; U Saxena; I D Goldberg; S Pillarisetti
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

4.  Apolipoprotein E inhibits neointimal hyperplasia after arterial injury in mice.

Authors:  B Zhu; D G Kuhel; D P Witte; D Y Hui
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 5.  Prostacyclin and the vascular endothelium.

Authors:  S Moncada; J R Vane
Journal:  Bull Eur Physiopathol Respir       Date:  1981

6.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

7.  Antiproliferative properties of sphingosine 1-phosphate in human hepatic myofibroblasts. A cyclooxygenase-2 mediated pathway.

Authors:  J Davaille; C Gallois; A Habib; L Li; A Mallat; J Tao; T Levade; S Lotersztajn
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

8.  Apolipoprotein E inhibition of vascular smooth muscle cell proliferation but not the inhibition of migration is mediated through activation of inducible nitric oxide synthase.

Authors:  M Ishigami; D K Swertfeger; M S Hui; N A Granholm; D Y Hui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-04       Impact factor: 8.311

9.  Stimulation of vascular smooth muscle cell prostacyclin and prostaglandin E2 synthesis by plasma high and low density lipoproteins.

Authors:  K B Pomerantz; A R Tall; S J Feinmark; P J Cannon
Journal:  Circ Res       Date:  1984-05       Impact factor: 17.367

10.  Human endothelial cells: use of heparin in cloning and long-term serial cultivation.

Authors:  S C Thornton; S N Mueller; E M Levine
Journal:  Science       Date:  1983-11-11       Impact factor: 47.728

View more
  18 in total

Review 1.  Apolipoprotein E-induced cell signaling in the vessel wall.

Authors:  David Y Hui
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

2.  Cyclooxygenase products and atherosclerosis.

Authors:  Macrae F Linton; Sergio Fazio
Journal:  Drug Discov Today Ther Strateg       Date:  2008

3.  Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222.

Authors:  Devashish Kothapalli; Paola Castagnino; Daniel J Rader; Michael C Phillips; Sissel Lund-Katz; Richard K Assoian
Journal:  Atherosclerosis       Date:  2012-12-19       Impact factor: 5.162

4.  ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma.

Authors:  Wijtske Annema; Arne Dikkers; Jan Freark de Boer; Thomas Gautier; Patrick C N Rensen; Daniel J Rader; Uwe J F Tietge
Journal:  J Lipid Res       Date:  2012-03-01       Impact factor: 5.922

Review 5.  Cell-specific production, secretion, and function of apolipoprotein E.

Authors:  Maaike Kockx; Mathew Traini; Leonard Kritharides
Journal:  J Mol Med (Berl)       Date:  2018-03-07       Impact factor: 4.599

Review 6.  High-density lipoprotein: a novel target for antirestenosis therapy.

Authors:  Kai Yin; Devendra K Agrawal
Journal:  Clin Transl Sci       Date:  2014-07-15       Impact factor: 4.689

Review 7.  The key role of apolipoprotein E in atherosclerosis.

Authors:  Kirsty Greenow; Nigel J Pearce; Dipak P Ramji
Journal:  J Mol Med (Berl)       Date:  2005-04-13       Impact factor: 4.599

8.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

9.  Apolipoprotein E inhibition of vascular hyperplasia and neointima formation requires inducible nitric oxide synthase.

Authors:  Zachary W Q Moore; David Y Hui
Journal:  J Lipid Res       Date:  2005-08-01       Impact factor: 5.922

10.  Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening.

Authors:  Devashish Kothapalli; Shu-Lin Liu; Yong Ho Bae; James Monslow; Tina Xu; Elizabeth A Hawthorne; Fitzroy J Byfield; Paola Castagnino; Shilpa Rao; Daniel J Rader; Ellen Puré; Michael C Phillips; Sissel Lund-Katz; Paul A Janmey; Richard K Assoian
Journal:  Cell Rep       Date:  2012-10-25       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.